Cumulus Neuroscience announced a collaboration with Muse by Interaxon to integrate Muse’s at-home sleep EEG into the NeuLogiq Platform, adding objective brain-based sleep measurement to a multi-modal suite for central nervous system clinical trials.
The integration was announced on 6 July 2026 from Belfast, Northern Ireland, Dublin and Toronto and will debut at the Alzheimer’s Association International Conference in London on 12–15 July at Cumulus Booth 712.
The Muse wearable reads brain activity at home and captures slow waves, spindles and K-complexes, and scores full sleep architecture with 88–96% agreement with gold-standard polysomnography, according to the company.
Cumulus presents the feature as trial-grade, low-burden sleep staging that complements NeuLogiq core measures of cognition, wake EEG, mood and speech.
Muse claims its platform has supported more than 16.8 million nights across 500,000+ users, is underpinned by 200+ third-party studies and contains over one billion minutes of decoded brain data.
The collaboration is positioned as enabling scalable, objective sleep biomarkers for decentralized CNS studies, according to Cumulus.
